Jagsonpal Pharmaceuticals Stock Screener | Share Price & Fundamental Analysis
JAGSNPHARM
Pharmaceuticals
Share Price NSE
₹194.62
▲
1.69 (0.88%)
Share Price BSE
₹194.95
▲
2.15 (1.12%)
As of April 13, 2026, the Jagsonpal Pharmaceuticals share price (NSE: JAGSNPHARM) is ₹194.62 on NSE and ₹194.95 on BSE, up 0.88% from the previous close, with shares trading between ₹189.41 and ₹197.45, and a 52-week range of ₹161.07–₹292.75.
Browse Jagsonpal Pharmaceuticals financial data to support your investment research.
Record your trades in TickJournal's free trading journal and track your portfolio performance.
Jagsonpal Pharmaceuticals Market Cap
₹1,313.73 Cr.
JAGSNPHARM P/E Ratio (TTM)
31.55
Jagsonpal Pharmaceuticals P/B Ratio
5.10
EPS (TTM)
₹8.26
Dividend Yield
1.29%
Debt to Equity
0.04
JAGSNPHARM 52 Week High
₹292.75
Jagsonpal Pharmaceuticals 52 Week Low
₹161.07
Operating Margin
19.00%
Profit Margin
13.99%
JAGSNPHARM Revenue (TTM)
₹293.00
EBITDA
₹65.00
Net Income
₹41.00
Total Assets
₹278.00
Total Equity
₹240.00
Jagsonpal Pharmaceuticals Share Price History - Stock Screener Chart
Screen JAGSNPHARM historical share price movements with interactive charts. Analyze price trends and patterns.
Jagsonpal Pharmaceuticals Company Profile - Fundamental Screener
Screen Jagsonpal Pharmaceuticals company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for JAGSNPHARM shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE048B01035
Jagsonpal Pharmaceuticals Balance Sheet Screener
Screen JAGSNPHARM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 278 | 217 | 195 | 164 | 164 | 147 | 136 | 130 | 143 | 159 |
| Current Assets | 161 | 199 | 165 | 109 | 121 | 95 | 98 | 95 | 110 | 101 |
| Fixed Assets | 95 | 9 | 24 | 23 | 26 | 22 | 22 | 21 | 22 | 52 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 12 | 11 | 9 | 5 | 2 | 3 | 3 | 3 | 3 | 4 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 240 | 187 | 159 | 133 | 122 | 111 | 105 | 98 | 110 | 98 |
| Share Capital | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Reserves & Surplus | 226 | 174 | 146 | 120 | 109 | 98 | 91 | 85 | 97 | 85 |
Jagsonpal Pharmaceuticals Income Statement Screener - Profit & Revenue Analysis
Screen Jagsonpal Pharmaceuticals income statement and profit fundamentals.
Analyze JAGSNPHARM quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Jagsonpal Pharmaceuticals share price evaluation.
| Item | None-None | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 293 | 277 | 218 | 242 | 221 | 192 | 161 | 168 | 127 | 144 | 144 | 138 |
| Expenses | 228 | 218 | 186 | 203 | 193 | 169 | 150 | 158 | 138 | 138 | 132 | 129 |
| EBITDA | 65 | 59 | 32 | 40 | 29 | 24 | 11 | 11 | -11 | 6 | 13 | 9 |
| Operating Profit % | 19.00% | 19.00% | 11.00% | 14.00% | 12.00% | 10.00% | 5.00% | 6.00% | -9.00% | 4.00% | 8.00% | 6.00% |
| Depreciation | 9 | 8 | 2 | 1 | 2 | 1 | 1 | 1 | 0 | 2 | 3 | 3 |
| Interest | 1 | 1 | 1 | 0 | 0 | 1 | 1 | 1 | 1 | 3 | 5 | 5 |
| Profit Before Tax | 54 | 70 | 30 | 35 | 27 | 22 | 9 | 9 | -12 | 14 | 4 | 2 |
| Tax | 12 | 15 | 7 | 8 | 8 | 5 | 2 | 2 | 0 | 3 | 1 | 1 |
| Net Profit | 41 | 55 | 23 | 27 | 19 | 17 | 8 | 7 | -12 | 12 | 3 | 1 |
| EPS | 6.10 | 8.26 | 8.49 | 10.20 | 7.20 | 6.51 | 3.00 | 2.75 | -4.41 | 4.53 | 1.24 | 0.45 |
Jagsonpal Pharmaceuticals Cash Flow Screener - Liquidity Fundamentals
Screen JAGSNPHARM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 55 | 35 | 47 | 7 | 28 | 11 | 31 | -2 | -3 | 9 |
| Investing Activities | -45 | -25 | -58 | -26 | -2 | -11 | -1 | -3 | 41 | -2 |
| Financing Activities | -12 | -9 | -1 | -18 | -7 | -1 | -6 | -1 | -34 | -6 |
| Net Cash Flow | -2 | 2 | -12 | -36 | 19 | -1 | 24 | -6 | 5 | 1 |
Jagsonpal Pharmaceuticals Shareholding Pattern Screener
See Jagsonpal Pharmaceuticals shareholding pattern with promoter, FII, and DII holdings.
Check Jagsonpal Pharmaceuticals promoter holding and ownership changes for JAGSNPHARM on TickJournal.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 67.78% | 67.65% | 67.54% | 67.39% | 68.09% | 68.04% | 67.97% | 67.81% |
| FII Holding | 2.10% | 2.18% | 2.12% | 2.12% | 0.73% | 1.10% | 2.30% | 2.10% |
| DII Holding | 0.00% | 0.05% | 0.09% | 0.15% | 0.85% | 0.85% | 0.11% | 0.00% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 20.94% | 24.26% | 21.13% | 21.20% | 20.69% | 20.79% | 20.38% | 20.64% |
| Other Holding | 9.17% | 5.86% | 9.12% | 9.14% | 9.64% | 9.22% | 9.24% | 9.45% |
| Shareholder Count | 21,085 | 22,899 | 24,653 | 24,895 | 16,282 | 15,748 | 15,633 | 18,471 |
Jagsonpal Pharmaceuticals Share Dividend Screener - Share Yield Analysis
Check Jagsonpal Pharmaceuticals dividend history with payout and yield data.
View Jagsonpal Pharmaceuticals dividend details including ex-dates and amounts for JAGSNPHARM stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹2.50 | 1.36% |
| 2024-March | ₹5.00 | 2.30% |
| 2023-March | ₹5.00 | 4.52% |
| 2022-March | ₹4.00 | 3.45% |
| 2021-March | ₹1.00 | 0.80% |
| 2020-March | ₹0.50 | 1.57% |
| 2019-March | ₹0.25 | 3.56% |
| 2018-March | ₹0.10 | 0.95% |
| 2017-March | ₹0.10 | 0.93% |
Jagsonpal Pharmaceuticals Stock Index Membership
See which indices include Jagsonpal Pharmaceuticals stock.
Check JAGSNPHARM index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
Jagsonpal Pharmaceuticals Market Events Screener - Corporate Actions
Get Jagsonpal Pharmaceuticals corporate actions including splits, bonuses, and buybacks.
Check Jagsonpal Pharmaceuticals stock events that may affect JAGSNPHARM share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | 13.27% | ||
| Dividend | ₹ 1.00 /share | 0.03% | ||
| Annual General Meeting | NA | -8.46% | ||
| Dividend | ₹ 2.50 /share | -0.52% | ||
| Dividend | ₹ 5.00 /share | 15.52% | ||
| 2026-01-21 | 2026-01-21 | Quarterly Result Announcement | NA | -2.74% |
| 2025-11-03 | 2025-11-03 | Quarterly Result Announcement | NA | 3.30% |
| 2025-07-26 | 2025-07-26 | Quarterly Result Announcement | NA | 1.09% |
| 2025-05-06 | 2025-05-06 | Quarterly Result Announcement | NA | 7.40% |
| 2025-01-22 | 2025-01-22 | Quarterly Result Announcement | NA | 2.48% |
| 2025-01-08 | 2024-10-23 | Split | 2:5 | 0.00% |
| 2024-10-23 | 2024-10-23 | Quarterly Result Announcement | NA | 0.30% |
| 2023-08-21 | 2023-08-21 | Dividend | ₹ 5.00 /share | 29.44% |
| 2022-06-17 | 2022-06-17 | Extraordinary General Meeting | NA | -5.05% |
| 2021-10-29 | 2021-11-01 | Dividend | ₹ 4.00 /share | 7.86% |
Jagsonpal Pharmaceuticals Competitors Screener - Peer Comparison
Screen JAGSNPHARM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 395,051 | 36.25 | 54,729 | 9.71% | 10,980 | 34.03 |
| Divis Laboratories | 160,555 | 65.53 | 9,712 | 18.67% | 2,191 | 53.67 |
| Torrent Pharmaceuticals | 141,832 | 61.93 | 11,539 | 6.99% | 1,911 | 47.83 |
| Lupin | 106,368 | 22.84 | 22,910 | 13.74% | 3,306 | 57.51 |
| Dr Reddys Laboratories | 101,743 | 18.62 | 33,741 | 16.73% | 5,725 | 45.58 |
| Cipla | 98,024 | 21.91 | 28,410 | 7.12% | 5,291 | 40.75 |
| Zydus Life Science | 92,639 | 18.33 | 23,511 | 18.55% | 4,615 | 57.32 |
| Mankind Pharma | 85,451 | 47.59 | 12,744 | 20.90% | 2,007 | 51.63 |
| Aurobindo Pharma | 77,926 | 22.50 | 32,346 | 9.43% | 3,484 | 65.82 |
| Alkem Laboratories | 64,595 | 26.85 | 13,458 | 3.70% | 2,216 | 53.68 |
Jagsonpal Pharmaceuticals Company Announcements - News Screener
Screen JAGSNPHARM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-04-12 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-26 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-03-26 | Closure of Trading Window | - |
| 2026-03-25 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | - |
| 2026-03-13 | Announcement Under Regulation 30 Of Sebi LODR | - |
| 2026-03-12 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-03-12 | Board Meeting Outcome for Outcome Of Board Meeting | - |
| 2026-03-09 | Board Meeting Intimation for Proposal Of Buyback Of Equity Shares Of The Company | - |
| 2026-03-09 | Announcement Under Regulation 30 Of SEBI LODR | - |
| 2026-03-09 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-03-09 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2026-01-27 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | - |
| 2026-01-22 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | - |
| 2026-01-22 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2026-01-21 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-01-21 | Announcement under Regulation 30 (LODR)-Investor Presentation | - |
| 2026-01-21 | Outcome Of Board Meeting Held On January 21 2026 Along With Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025 | - |
| 2026-01-21 | Board Meeting Outcome for Outcome Of Board Meeting Held On January 21 2026 Along With Unaudited Financial Results For The Quarter And Nine Months Ended December 31 2025 | - |
| 2026-01-15 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-01-13 | Board Meeting Intimation for Intimation Of Board Meeting | - |